A brief discussion on the practical necessity of adjusting the prevention and control strategy of COVID-19 in China

doi:10.19871/j.cnki.xfcrbzz.2023.01.001

Abstract

Abstract: The pandemic of SARS-CoV-2 lasts for three yeas since the outbreak, and has become the most significant public health emergency of the 20th century. This paper reviews trends in the global pandemic over the past three years, systematically analyzes the epidemiological properties, pathogenic characteristics, clinical features, and effectiveness of various interventions over time. Our study focuses on comprehensive factors to be considered for adjusting prevention and control strategies under the new situation, including pathogen and transmission characteristics, immune barriers, disease burden and hazards, therapeutic progress. We aim to make recommendations for the prevention and control of SARS-CoV-2 infections in terms of resource preparation, establishment of surveillance system, vaccination of key populations, health promotion, and we believe this experience will provide useful reference for the emergency response and comprehensive prevention and control of new infectious diseases in the future.

Key words: Corona virus disease 2019, Prevention and control strategies, Suggestions for response

CLC Number:

R19-0
R511

Feng Siyang, Lu Jianhua, Liao Yuxue, Zhang Zhen, Guo Yansheng, Lyv Qiuying, Kong Dongfeng, Chen Zhigao, Zou Xuan, Feng Tiejian, Liao Yi. A brief discussion on the practical necessity of adjusting the prevention and control strategy of COVID-19 in China[J]. Electronic Journal of Emerging Infectious Diseases, 2023, 8(1): 1-7.

References

[1] MSEMBURI W, KARLINSKY A, KNUTSON V, et al.The WHO estimates of excess mortality associated with the COVID-19 pandemic[J]. Nature, 2023, 613(7942):130-137.
[2] WORLD HEALTH ORGANIZATION. WHO Coronavirus (COVID-19) Dashboard[EB/OL]. [2023-01-11].https://covid19.who.int/.
[3] RIBEIRO XC, SACHETTO OR, DA FVV, et al.Characterisation of Omicron Variant during COVID-19 Pandemic and the Impact of Vaccination, Transmission Rate, Mortality, and Reinfection in South Africa, Germany, and Brazil[J]. BioTech (Basel), 2022, 11(2):1-15.
[4] 国务院应对新型冠状病毒感染疫情联防联控机制综合组.关于对新型冠状病毒感染实施“乙类乙管”的总体方案[EB/OL].[2022-12-26]. http://www.gov.cn/xinwen/2022-12/27/content_5733739.htm.
[5] AMICONE M, BORGES V, ALVES MJ, et al.Mutation rate of SARS-CoV-2 and emergence of mutators during experimental evolution[J]. Evol Med Public Health, 2022, 10(1):142-155.
[6] LIU Y, ROCKLOV J.The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta[J]. J Travel Med, 2022,29(3):c37.
[7] WU Y, KANG L, GUO Z, et al.Incubation Period of COVID-19 Caused by Unique SARS-CoV-2 Strains: A Systematic Review and Meta-analysis[J]. JAMA Netw Open, 2022, 5(8):e2228008.
[8] 廖春晓, 王波, 吕筠, 等. 新型冠状病毒Omicron变异株病原学及流行病学研究进展[J]. 中华流行病学杂志, 2022,43(11):1691-1698.
[9] LYU K, FENG S, LI X, et al.SARS-CoV-2 Aerosol Transmission Through Vertical Sanitary Drains in High-Rise Buildings-Shenzhen, Guangdong Province, China, March 2022[J]. China CDC Wkly, 2022, 4(23):489-493.
[10] ZHANG Z, LI X, WANG Q, et al.Field Simulation of Aerosol Transmission of SARS-CoV-2 in a Special Building Layout - Guangdong Province, China, 2021[J]. China CDC weekly, 2021, 3(34):711-715.
[11] HUANG C, WANG Y, LI X, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223):497-506.
[12] SHUAI H, CHAN JF, HU B, et al.Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron[J]. Nature, 2022, 603(7902):693-699.
[13] DYER O.Covid-19: South Africa's surge in cases deepens alarm over omicron variant[J]. BMJ, 2021, 375:n3013.
[14] TIAN D, SUN Y, XU H, et al.The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant[J]. J Med Virol, 2022, 94(6):2376-2383.
[15] WORLD HEALTH ORGANIZATION.COVID-19 Research and Innovation: Powering the world's pandemic response - now and in the future[R]. Geneva: 2022.
[16] THOMPSON M G, STENEHJEM E, GRANNIS S, et al.Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings[J]. N Engl J Med, 2021, 385(15):1355-1371.
[17] CHEUNG PH, CHAN CP, JIN DY.Lessons learned from the fifth wave of COVID-19 in Hong Kong in early 2022[J]. Emerg Microbes Infect, 2022, 11(1):1072-1078.
[18] KEEHNER J, HORTON LE, BINKIN NJ, et al.Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce[J]. N Engl J Med, 2021, 385(14):1330-1332.
[19] ZHANG L, LI Q, LIANG Z, et al.The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron[J]. Emerg Microbes Infect, 2022, 11(1):1-5.
[20] PULLIAM J, VAN SCHALKWYK C, GOVENDER N, et al.Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa[J]. Science, 2022, 376(6593):n4947.
[21] 李倩, 卢洪洲. 新型冠状病毒疫苗研究最新进展[J/CD]. 新发传染病电子杂志, 2020, 5(4):268-273.
[22] LAI S, RUKTANONCHAI NW, ZHOU L, et al.Effect of non-pharmaceutical interventions to contain COVID-19 in China[J]. Nature, 2020, 585(7825):410-413.
[23] 吕秋莹, 梅树江, 张仁利, 等. 新型冠状病毒肺炎精准防控体系构建与效果评价[J/CD]. 新发传染病电子杂志, 2020, 5(4):229-233.
[24] PETERSEN E, KOOPMANS M, GO U, et al.Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics[J]. Lancet Infect Dis, 2020, 20(9):e238-e244.
[25] WANG X, SHI L, ZHANG Y, et al.Policy disparities in fighting COVID-19 among Japan, Italy, Singapore and China[J]. Int J Equity Health, 2021, 20(1):1-11.
[26] ZHANG J, YANG H, YANG M, et al.The role of vaccines in COVID-19 control strategies in Singapore and China[J]. Health Policy Technol, 2022,11(2):100620.
[27] SONG P, MITSUYA H, KOKUDO N.COVID-19 in Japan: An update on national policy, research, clinical practice, and vaccination campaign[J]. Glob Health Med, 2022, 4(2):64-66.
[28] WONG C, AU I, LAU K, et al.Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study[J]. Lancet Infect Dis, 2022,22(12):1681-1693.
[29] YIN W, XU Y, XU P, et al.Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody[J]. Science, 2022, 375(6584):1048-1053.
[30] SUZUKI R, YAMASOBA D, KIMURA I, et al.Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant[J]. Nature, 2022, 603(7902):700-705.
[31] 廖康生, 卢洪洲. 新型冠状病毒奥密克戎变异株的研究进展:对其科学防控措施的启示[J/CD]. 新发传染病电子杂志, 2022, 7(1):1-5.
[32] DAVIES N G, ABBOTT S, BARNARD R C, et al.Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England[J]. Science, 2021, 372(6538):g3055.
[33] CHOI J Y, SMITH DM.SARS-CoV-2 Variants of Concern[J]. Yonsei Med J, 2021, 62(11):961-968.
[34] LIU Y, ROCKLOV J.The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus[J]. J Travel Med, 2021, 28(7):b124.
[35] GRANT R, CHARMET T, SCHAEFFER L, et al.Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France[J]. Lancet Reg Health Eur, 2022, 13:100278.
[36] SARS-COV-2 VARIANT WITH LINEAGE B.1.351 CLUSTERS INVESTIGATION TEAM; MEMBERS OF THE SARS-COV-2 VARIANT WITH LINEAGE B.1.351 CLUSTERS INVESTIGATION TEAM.Linked transmission chains of imported SARS-CoV-2 variant B.1.351 across mainland France, January 2021SARS-COV-2 VARIANT WITH LINEAGE B.1.351 CLUSTERS INVESTIGATION TEAM; MEMBERS OF THE SARS-COV-2 VARIANT WITH LINEAGE B.1.351 CLUSTERS INVESTIGATION TEAM.Linked transmission chains of imported SARS-CoV-2 variant B.1.351 across mainland France, January 2021[J]. Euro Surveill, 2021, 26(13):2100333.
[37] FUNK T, PHARRIS A, SPITERI G, et al.Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021[J]. Euro Surveill, 2021, 26(16):2100348.
[38] LI D, LI AE, LI ZQ, et al.SARS-CoV-2 Delta Variant in Jingmen City, Hubei Province, China, 2021: Children Susceptible and Vaccination Breakthrough Infection[J]. Front Microbiol, 2022, 13:856757.
[39] HOUHAMDI L, GAUTRET P, HOANG V T, et al.Characteristics of the first 1119 SARS-CoV-2 Omicron variant cases, in Marseille, France, November-December 2021[J]. J Med Virol, 2022, 94(5):2290-2295.
[40] CHALLEN R, BROOKS-POLLOCK E, READ JM, et al.Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study[J]. BMJ, 2021, 372:n579.
[41] ONG S, CHIEW CJ, ANG LW, et al.Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta)[J]. Clin Infect Dis, 2022, 75(1):e1128-e1136.
[42] WOLTER N, JASSAT W, WALAZA S, et al.Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study[J]. Lancet, 2022, 399(10323):437-446.